CARIS LIFE SCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
CARIS LIFE SCIENCES, INC. (CAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $17.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-03
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $5.20M, a 48.57% increase year-over-year.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-06-30 was $3.50M.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $17.30M, a 28.15% increase from fiscal 2024.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $13.50M, a 29.81% increase from fiscal 2023.
- CARIS LIFE SCIENCES, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $10.40M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|
| 2025-12-31 | $17.30M 10-K · filed 2026-03-03 | ||
| 2025-06-30 | $5.20M 10-Q · filed 2025-08-12 | $19.60M 10-Q · filed 2025-08-12 | |
| 2024-12-31 | $13.50M 10-K · filed 2026-03-03 | ||
| 2024-06-30 | $3.50M 10-Q · filed 2025-08-12 | $4.80M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $10.40M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |